Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07189871 · ClinicalTrials.gov registry record · Phase 1
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Radiopharm Theranostics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 2
- Study locations
NCT07189871: Recruiting Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Radiopharm Theranostics.
NCT07189871 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Radiopharm Theranostics. The registered enrollment target is 61 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07189871, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Radiopharm Theranostics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Primary Outcome
Incidence of dose-limiting toxicities (DLTs) during the 6 weeks following the first 177Lu-BetaBart injection
Conditions Studied
Interventions
- DRUG 177Lu-BetaBart
Study Locations (2)
Michigan
- BAMF Health - Grand Rapids
Nebraska
- Nebraska Cancer Specialists - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT07189871 shows while recruiting
NCT07189871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which 177Lu-BetaBart is the first listed.
NCT07189871 reports a single indexed study location in Michigan, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07189871 about?
NCT07189871 is a clinical study titled "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors". A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
What is the current status of trial NCT07189871?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2026-02. Estimated completion is 2027-12.
What conditions does trial NCT07189871 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, TNBC - Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT07189871?
The interventions under investigation include: 177Lu-BetaBart (DRUG).
Who is sponsoring clinical trial NCT07189871?
This trial is sponsored by Radiopharm Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07189871 being conducted?
This trial has 2 study locations across Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07189871's enrollment target sits among peer trials
61 257th of 381 higher than 125 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia